Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q. Management blamed the poor sales performance on “U.S. hospital staffing shortages and COVID headwinds in Japan.” Analysts commented that the slowdown seems “strangely sudden” and inconsistent “across the rest of MedTech.”
Following this news, Edwards’s stock price fell by $15.43 per share, or approximately 18% to close at $70.87 per share.